Short stature and growth hormone use in pediatric hemodialysis patients

被引:0
|
作者
Gregory Gorman
Barbara Fivush
Diane Frankenfield
Bradley Warady
Sandra Watkins
Andrew Brem
Alicia Neu
机构
[1] Johns Hopkins University School of Medicine,The Centers for Medicare & Medicaid Services (CMS)
[2] Office of Clinical Standards and Quality,Pediatric Nephrology
[3] The Children’s Mercy Hospital,undefined
[4] University of Washington/Children’s Hospital,undefined
[5] Rhode Island Hospital,undefined
[6] Johns Hopkins University,undefined
来源
Pediatric Nephrology | 2005年 / 20卷
关键词
Adolescents; Growth; Hemodialysis;
D O I
暂无
中图分类号
学科分类号
摘要
End-stage renal disease (ESRD) causes growth retardation in children, and poor growth has been linked to worse outcomes. Recombinant human growth hormone (rhGH) can increase growth velocity and final adult height in pediatric ESRD patients. We aimed to identify clinical predictors of short stature (height standard deviation score (Ht SDS) <−1.88) and rhGH use in short stature pediatric hemodialysis patients. In 2002, the Centers for Medicare & Medicaid Services (CMS) Clinical Performances Measures (CPM) ESRD Project collected demographic, clinical and laboratory data as well as rhGH use on all in-center hemodialysis patients in the US aged <18 years. The odds ratios (OR) of short stature and rhGH use for individual predictors were determined by multivariate logistic regression modeling. Six-hundred and fifty-one (92%) of 710 eligible patients were included for analysis. Of these, 266 (41%) had Ht SDS <−1.88. After adjustment, short stature was predicted by congenital / urologic causes of ESRD ((OR 5.4; 95% confidence interval [CI], 2.1–13.8; p <0.001) in patients aged 10–14 years; (OR 2.8; 95% CI, 1.5–5.4; p <0.01) in patients aged 15–18 years) and increasing years on dialysis ((OR 1.2; 95% CI, 1.1–1.4; p <0.01) in patients aged 10–14 years; (OR 1.2; 95% CI, 1.1–1.4; p <0.001) in patients aged 15–18 years). Of 266 short stature patients, 214 (80.5%) had data on rhGH use. Of these, 80 (37%) had been prescribed rhGH. After adjustment, use of rhGH in short-stature patients was predicted by white race (OR 2.1; 95% CI, 1.1–4.0; p <0.05), increasing years on dialysis (OR 1.13; 95% CI, 1.05–1.22; p <0.01) and patients with BMI <16.6 kg/m2 (OR 3.1; 95% CI, 1.2–8.4; p <0.05). Increasing age and level of intact parathyroid hormone were not associated with rhGH use among short stature patients. A significant proportion of pediatric hemodialysis patients have short stature. The majority of short-stature patients are not receiving rhGH. Patients with short stature who are white, have longer durations on dialysis and have lower BMI are more likely to receive rhGH.
引用
收藏
页码:1794 / 1800
页数:6
相关论文
共 50 条
  • [41] Identification of a growth hormone mutation responsible for short stature
    Chihara, K
    ACTA PAEDIATRICA, 1996, 85 : 49 - 50
  • [42] Psychosocial aspects of short stature and growth hormone therapy
    Sandberg, DE
    Kranzler, J
    Bukowski, WM
    Rosenbloom, AL
    JOURNAL OF PEDIATRICS, 1999, 135 (01): : 133 - 134
  • [43] Outcomes of Growth Hormone Therapy for Children with Short Stature
    Feldman, Matthew
    Huang, Carol
    Rath, Mitchell
    Hinkley, Cheyanne
    Perry, Rebecca
    Ho, Josephine
    Dawrant, Jonathan
    Luca, Paola
    Pacaud, Danielle
    Winston, Karin
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 (SUPPL 3): : 184 - 185
  • [44] Growth hormone safe in boy's of short stature
    不详
    AMERICAN JOURNAL OF NURSING, 2001, 101 (06) : 24CCCC - 24CCCC
  • [45] The Rationale for Growth Hormone Therapy in Children with Short Stature
    Deodati, Annalisa
    Cianfarani, Stefano
    JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, 2017, 9 : 23 - 32
  • [46] INVESTIGATION OF SHORT STATURE AND GROWTH-HORMONE DEFICIENCY
    POWELL, D
    IRISH MEDICAL JOURNAL, 1985, 78 (03) : 83 - 84
  • [47] Growth hormone therapy response in children with short stature
    Amira Ahmed Gad
    Radwa Shamma
    Mohamed A. Elmonem
    Nora E. Badawi
    Lubna Fawaz
    Mona Mamdouh Hassan
    Egyptian Pediatric Association Gazette, 71
  • [48] Should idiopathic short stature be treated with growth hormone?
    Savage, Martin O.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2009, 5 (03): : 148 - 149
  • [49] Should idiopathic short stature be treated with growth hormone?
    Martin O Savage
    Nature Reviews Endocrinology, 2009, 5 : 148 - 149
  • [50] Determinants of Short Stature and the Response to Growth Hormone Therapy
    Dunger, David B.
    HORMONE RESEARCH, 2009, 71 : 2 - 4